Ordering a single research peptide is usually a straightforward transaction: a catalogue number, a batch CoA, a tracked dispatch. Requesting a fixed blend is a different proposition. When a laboratory asks a UK supplier to prepare a defined mixture of two or more lyophilised compounds, a responsible supplier may slow the process down — and in some cases decline outright — until the laboratory can demonstrate that a new in-vitro assay has been booked, specified and documented. That pause is not obstruction for its own sake. It reflects how documentation, compliance screening and storage liability interact once a compound stops being a catalogue item and becomes a bespoke material.
Traceability, Batch Documentation and the Booking That Anchors a Blend
A single catalogue vial arrives with a defined identity: a SKU, an expiry reference and a batch CoA. A fixed blend is a different proposition entirely. Once two lyophilised compounds are combined into one vial, the supplier loses the one-to-one relationship between compound, batch and certificate on which its quality system is built. The shop describes batch-level analytical verification supporting purity, identity and contaminant screening, with CoAs linked to supported products. A blend sits outside that structure, because the document that accompanies a vial can only speak to what was tested — and what was tested was each compound separately.
The Internal Test Reference (ITR) illustrates the difficulty neatly. The FAQs explain that restocked products may carry the same ITR as earlier stock, and that an ITR links to associated sample testing reports; it does not confirm that separate deliveries come from the same production lot or have had separate independent testing. If a laboratory asks for a blend drawn from compounds held in different deliveries, the supplier cannot simply staple two certificates together and call the traceability chain complete. Excipient accounting adds a further wrinkle: the FAQs note that all peptides contain trace amounts of mannitol, so a blend carries a combined excipient load that no single-vial CoA describes.
This is where an assay booking becomes the anchor. A booked in-vitro assay — with a stated plate format, endpoint, diluent volume and target concentration for the well, plus a named operator and a disposal route — gives the supplier something a casual enquiry cannot: a documented purpose tying the material to a controlled laboratory workflow. It also gives the laboratory a defensible record if a batch is later questioned. When raising documentation queries, quote the vial label reference, which combines the SKU code and expiry date, so the CoA supplied with that specific batch can be retrieved and checked.
Compliance Screening: Reading the Intended-Use Statement in the Request
Research-use-only status is not a formality. Products are labelled “For Research Use Only – Not for Human Consumption”, described by the shop as being in line with MHRA guidance — a stated position, not legal advice. The shop does not supply materials for therapeutic, clinical or diagnostic purposes, and the purchaser carries responsibility for lawful use, safe handling, storage and disposal, for compliance with COSHH and laboratory safety standards, and for confirming that a product suits the intended research application.
A blend request is a natural point for that screening to intensify. Individual vials are ordered against a catalogue listing that already sets the permitted context. A blend asks a supplier to create something new, and the accompanying correspondence often reveals what the material is actually for. Enquiries framed around administration to a person or an animal, quantities sized for anything other than a defined in-vitro endpoint, or handling instructions borrowed from a clinical setting will normally stop an order at the first review. The About page confirms that the company does not provide therapeutic, medical, performance, injection, ingestion or dosing guidance, and that orders inconsistent with its compliance standards may be refused.
The practical consequence is that some suppliers will not prepare a fixed blend under any circumstances. The FAQs state plainly that the shop does not supply blended peptides — the example given is Ipamorelin combined with CJC-1295 — and instead recommends buying peptides individually and combining them only within a controlled experimental design. Researchers weighing up options can see how each compound is listed and documented on its own through Peptides uk; single-vial listings keep the CoA, storage guidance and label reference attached to one compound at a time, which is generally the stronger position for an assay that has to be reproducible months later. Materials supplied under these terms remain not for human or veterinary use.
Handling, Storage and Fulfilment: The Practical Reasons Behind a Hold
Stability is the least glamorous reason for a refusal and often the decisive one. The shop’s handling guidance is clear for single compounds: lyophilised peptides stored at –20°C or below, sealed with desiccant, protected from moisture, heat and light, with repeated freeze–thaw cycles avoided; reconstituted material is less stable and should be held at 2–8°C for short-term laboratory use. None of that guidance describes how two compounds behave when combined in one vial, and a supplier has no batch-specific evidence to offer on the point. Holding the order until an assay is booked allows the dilution scheme to be settled in advance, so reconstitution happens once, at a concentration the in-vitro workflow actually requires. The free reconstitution calculator described on product pages and in the FAQs is for laboratory research only and must never be used for human or veterinary dosing.
Fulfilment terms add a second layer of hesitation. The shop states that orders are dispatched the next working day, shipped by Royal Mail Tracked 24, which usually delivers the following working day as a Royal Mail estimate; tracking is issued after dispatch and timings can vary in peak periods. The homepage’s “24hr UK Delivery” line is marketing wording rather than a guaranteed arrival date. With no returns once dispatched, and refunds limited to damage, incorrect supply or quality issues under the Refunds & Returns Policy, a bespoke blend is awkward to place within those terms — if the assay is cancelled midway, neither party has a clean resolution.
Payment review can delay a custom request too. As described in the FAQs and a March 2026 blog post, the shop uses Pay-By-Bank / Open Banking through providers such as Wallid, regulated by the FCA, and does not accept card payments because research-use-only scientific materials fall into high-risk merchant categories; it says it does not store bank login details. An enquiry that arrives with unclear provenance or an unusual payment route may be paused for exactly the reasons it was paused at the documentation stage.
Finally, published figures are worth reading carefully rather than assuming. The homepage lists “≥99% Verified Purity”, “3,000+ UK Orders”, “7 Days Expert Customer Support” and “CoAs Janoshik Analytical Reports”. Treat these as the shop’s current published wording, reconfirm them on the live site, and remember that exact purity for a given vial is stated on the CoA for that batch — open the document that arrives with the material rather than relying on a headline percentage. The same discipline applies to any blend request: without an assay to anchor it, the paperwork cannot follow the sample, and a careful supplier will say so before taking payment.
Lisbon-born chemist who found her calling demystifying ingredients in everything from skincare serums to space rocket fuels. Artie’s articles mix nerdy depth with playful analogies (“retinol is skincare’s personal trainer”). She recharges by doing capoeira and illustrating comic strips about her mischievous lab hamster, Dalton.